Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

Oversight of US genetic testing laboratories

Article Abstract:

The relationship between improved quality of genetic testing and laboratory quality and the attitudes of laboratory directors toward current genetic testing regulation, the value of a genetic testing specialty and the value of PT in ensuring quality testing are examined to explore whether the creation of a genetic testing with specific proficiency testing (PT) standards could improve the quality of genetic testing. The data from the survey clearly demonstrates that laboratory directors support moves to create formal registration under genetic testing specially for centers that carry out such analyses.

Author: Scott, Joan, Hudson, Kathy L., Murphy, Juli A., Kaufman, David J., Javitt, Gail H., Katsanis, Sara H.
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
Product quality, Quality management, Genetic screening, Genetic testing, Biotechnology laboratories

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Errors in patent application sequence listings

Article Abstract:

The reality of preparing a patent application involves research and legal staff in multiple rounds of writing, editing and review. The most frequent errors identified at the US Patent and Trademark Office include files not being submitted as plain text, incorrect line lengths and line wrapping, missing tags and invalid sequence features, especially those that describe ambiguities in the reported sequence.

Author: Jones, Robert
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2003
Evaluation, Patent literature

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


An individual approach

Article Abstract:

The US Food and Drug Administration has released guidelines in March 2005 that encourage, but do not require, companies to provide pharmacogenomic data in new applications for drug approval. This information would predict how a patient might respond to a drug based on their genetic profile, both the gene variants they have inherited and the expression pattern of those genes.

Author: Lewis, Ricki
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
General services, Pharmaceutical preparations, Pharmaceutical industry, Company systems management, Information management, United States. Food and Drug Administration, Pharmacogenetics, Pharmacogenomics

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Standards, United States
Similar abstracts:
  • Abstracts: Measuring the efficiency of multiunit banking: an activity analysis approach. Regional reciprocal interstate banking: the Supreme Court and the resolution of uncertainty
  • Abstracts: Comparison of alternative pest and soil management strategies for Maine potato production systems. Soil improvement following addition of chipped wood from twigs
  • Abstracts: Considering the impact of medicine label design characteristics on patient safety. Effect of caffeine on target detection and rifle marksmanship
  • Abstracts: Vale to Trevor Johnston. Sensitivity of executive pay to accounting performance measures in all-equity firms. Efficient contracting and accounting
  • Abstracts: Mechanisms of gene silencing by double-stranded RNA. Engineering synthetic signaling proteins with ultrasensitive input/output control
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.